With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6737-42-4,1,3-Bis(diphenylphosphino)propane,as a common compound, the synthetic route is as follows.
6737-42-4, Preparation 12 A mixture of 4-[2-(tert-butoxycarbonylamino)ethyl]-phenyl trifluoromethanesulfonate (6.11 g, 16.6 mmol), palladium(II) acetate (745 mg, 3.32 mmol), 1,3-bis-(diphenylphosphino)propane (1.37 g, 3.32 mmol), triethylamine (6.94 ml, 49.8 mmol), and MeOH (24ml) in DMF (60 ml) was purged for 30 min with carbon monoxide. The mixture was stirred under carbon monoxide atmosphere at 78 C. for 3 hours. After cooling the mixture to room temperature, the reaction mixture was diluted with EtOAc, washed with water, 1N-hydrochloric acid, water, saturated sodium hydrogencarbonate, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 4:1-3:1) to give methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate (3.52 g, 76%). IR (KBr, cm-1): 3371, 2978, 2947, 1722, 1680, 1525, 1277 1H-NMR (CDCl3, delta): 1.43 (9H, s), 2.86 (2H, t, J=7.0 Hz),3.32-3.45 (2H, m), 3.91 (3H, s), 4.45-4.63 (1H, m), 7.27 (2H, d, J=8.3 Hz), 7.98 (2H, d, J=8.3 Hz) MS (m/z): 1 80 (M-C5H9O2+2H)+
6737-42-4 1,3-Bis(diphenylphosphino)propane 81219, achiral-phosphine-ligands compound, is more and more widely used in various fields.
Reference£º
Patent; Fujisawa Pharmaceutical Co., Ltd.; US6437146; (2002); B1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate